# reload+after+2024-01-22 16:44:11.408618
address1§149 Commonwealth Drive
city§Menlo Park
state§CA
zip§94025
country§United States
phone§650 327 3270
fax§650 327 3218
website§https://www.corcept.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. It is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
fullTimeEmployees§299
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Joseph K. Belanoff M.D.', 'age': 66, 'title': 'Co-Founder, President, CEO & Director', 'yearBorn': 1957, 'fiscalYear': 2022, 'totalPay': 1816333, 'exercisedValue': 19308000, 'unexercisedValue': 31696408}, {'maxAge': 1, 'name': 'Mr. Atabak  Mokari', 'age': 46, 'title': 'CFO & Treasurer', 'yearBorn': 1977, 'fiscalYear': 2022, 'totalPay': 760750, 'exercisedValue': 0, 'unexercisedValue': 21875}, {'maxAge': 1, 'name': 'Dr. Hazel  Hunt Ph.D.', 'age': 63, 'title': 'Chief Scientific Officer', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 895156, 'exercisedValue': 1751850, 'unexercisedValue': 13169500}, {'maxAge': 1, 'name': 'Mr. Sean  Maduck', 'age': 46, 'title': 'President of Corcept Endocrinology', 'yearBorn': 1977, 'fiscalYear': 2022, 'totalPay': 823417, 'exercisedValue': 3370439, 'unexercisedValue': 15785800}, {'maxAge': 1, 'name': 'Mr. Gary Charles Robb', 'age': 60, 'title': 'Chief Business Officer & Secretary', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 963000, 'exercisedValue': 4815287, 'unexercisedValue': 12396773}, {'maxAge': 1, 'name': 'Mr. Joseph Douglas Lyon', 'age': 44, 'title': 'Chief Accounting Officer', 'yearBorn': 1979, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Amy  Flood', 'title': 'Chief Human Resources & Communications Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. William  Guyer Pharm.D.', 'age': 55, 'title': 'Chief Development Officer', 'yearBorn': 1968, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Monica  Tellado', 'age': 50, 'title': 'President of Emerging Markets', 'yearBorn': 1973, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§5
boardRisk§3
compensationRisk§8
shareHolderRightsRisk§6
overallRisk§6
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.387
priceToSalesTrailing12Months§5.561472
currency§USD
dateShortInterest§1702598400
forwardEps§0.78
pegRatio§-0.67
exchange§NCM
quoteType§EQUITY
shortName§Corcept Therapeutics Incorporat
longName§Corcept Therapeutics Incorporated
firstTradeDateEpochUtc§1081949400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§a461c3f8-0bad-368f-8e34-11b913003b11
gmtOffSetMilliseconds§-18000000
targetHighPrice§50.0
targetLowPrice§27.0
targetMeanPrice§35.67
targetMedianPrice§35.5
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§6
quickRatio§3.324
earningsGrowth§-0.067
grossMargins§0.98648
ebitdaMargins§0.21947001
trailingPegRatio§None
